Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.

Trial Details

NCT ID

NCT05584267

Phase

PHASE2

Sponsor

Hunan Province Tumor Hospital

Status

RECRUITING

Cancer Type

Small Cell (SCLC) Lung Cancer

Interventions

radiotherapy
Chemotherapy + immunotherapy

Locations (sample)

Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Age ≥ 18 years of age on day of signing informed consent
Histopathology confirmed non-small cell lung cancer
Asymptomatic brain metastases
EGFR/ALK ROS1 driver gene mutation negative

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →